Aptose Enters into Exclusive Worldwide License Agreement with Hanmi Pharmaceutical for Clinical-Stage Myeloid Kinome Inhibitor HM43239 Nov 04, 2021 6:00am EDT
Aptose to Report Third Quarter 2021 Financial Results and Hold Conference Call on Thursday, November 11, 2021 Oct 26, 2021 7:30am EDT
Aptose to Report Second Quarter 2021 Financial Results and Hold Conference Call on Tuesday, August 3, 2021 Jul 20, 2021 4:01pm EDT
